Sentences with phrase «with immune checkpoint»

Low - dose chemotherapy, radiation, or targeted therapies given in combination with immune checkpoint blockade may prove to be an effective and efficient way to immunize the body against tumor cells,» says CRI Scientific Advisory Council associate director James P. Allison, Ph.D., who identified the first immune checkpoint blockade with his discovery in 1995 that the cytotoxic T lymphocyte antigen - 4 (CTLA - 4) receptor inhibited T cell responses.

Gowans MF et al. (2018) Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.

However, the efficacy of oncolytic viruses still was modest, but can be improved when combined with immune checkpoint inhibitors.

EOS200271 has demonstrated anti-tumor activity in multiple preclinical tumor models in monotherapy and in combination with immune checkpoint inhibitors.

The designation is specifically for patients with locally advanced or metastatic urothelial cancer who have previously been treated with immune checkpoint inhibitors.

iTeos is now developing EOS200271 which is a synthetic, small molecule inhibitor of indoleamine 2,3 - dioxygenase (IDO1), which has demonstrated the same anti-tumour activity in multiple preclinical tumour models in combination with immune checkpoint inhibitors as competitors, but also has demonstrated superior brain penetration.

The researchers hypothesized that antibiotics might even have an effect 60 days from start of therapy with immune checkpoint inhibitors.

The data presented provide new insights on the potential mechanism by which Seres» microbiome therapies could improve the outcomes of cancer patients treated with immune checkpoint inhibitors.

«These results confirm that antibiotics - associated dysbiosis might be deleterious in patients treated with immune checkpoint inhibitors, suggesting that an intact gut microbiota is needed to mobilize the immune system regardless of the tumor site,» wrote Lisa Derosa, MD, of Gustave Roussy Cancer Campus, Villejuif, France, and colleagues.

ALEXANDRIA, VA, FORT WASHINGTON, PA. — Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer.

«Cancer treatment for transplant patients discovered: Letter notes combination of steroids and immunosuppressants, combined with immune checkpoint inhibitors helps prevent organ rejection in kidney transplant patients undergoing cancer treatment.»

Researchers led by Van Allen and Choueiri sought an explanation for why some patients with a form of metastatic kidney cancer called clear cell renal cell cancer (ccRCC) gain clinical benefit — sometimes durable — from treatment with immune checkpoint inhibitors that block the PD - 1 checkpoint, while other patients don't.

A cohort of patients treated with the immune checkpoint inhibitor ipilimumab (207 patients) showed similar results.

«Cancers evade immunotherapy by «discarding the evidence» of tumor - specific mutations: Discovery could explain widespread acquired resistance among patients treated with immune checkpoint blockade drugs.»

Researchers found the gene therapy approach had stronger results when used in combination with either depletion of immunosuppressive cells from the tumor mass or with immune checkpoint blockade.

Their study of fecal samples from 105 patients treated with immune checkpoint blockade indicates that certain characteristics of patients» microbiomes correlate with slower disease progression while other qualities are associated with rapid worsening of the disease.

Patients in the study were treated with immune checkpoint inhibitors that block the activation of PD1, a protein on immune system T cells that halts immune response.

The final aim is improving therapeutic effect and defining rationalized drug combinations with immune checkpoints and proprietary molecules developed by collaborators, including novel immunomodulatory approaches generated at our unit.

Not exact matches

In the most recent of these reports (in the latest issue of Science), Dr. Jennifer Wargo, a surgeon and research scientist at M.D. Anderson, along with several dozen colleagues at other institutions, reveal that the composition of a patient's gut microbiota can significantly influence whether he or she responds to an immune checkpoint inhibitor — the type of cancer immunotherapy that releases the emergency brakes in the car analogy above.

In a retrospective analysis of clinical trial data, they found that melanoma patients with highly aneuploid tumors were less likely to benefit from immune checkpoint blockade therapy than patients whose tumors showed fewer chromosomal disruptions.

Wrangle and Rubinstein's therapy is a combination of a checkpoint drug, nivolumab, with a new and powerful immune stimulation drug, ALT - 803.

Researchers at The University of Texas MD Anderson Cancer Center developed a novel chimeric mouse model to test the combination therapy using immune checkpoint blockades with therapies targeting myeloid - derived suppressor cells (MDSCs).

In my experience, this marks both the first clinical trial of an approved drug with an effect on survival in advanced melanoma in the adjuvant setting, and, in this same setting, the first to study an immune checkpoint inhibitor in the adjuvant setting.

One recent tally found more than 1100 studies combining a popular new class called checkpoint inhibitor drugs, which unleash suppressed immune cells, with other treatments.

«We wanted to utilize platelets» intrinsic tendencies to accumulate at wounds and to interact with circulating tumor cells, for targeted delivery of immune checkpoint inhibitors» said Gu, «Interestingly, we found the antibody can be promoted to release from activated platelets in the surgical site, due to generation of small platelet - derived microparticles upon the platelet activation.

In addition to anti-tumor responses, immune checkpoint inhibitors have also been associated with long - term remission in a subset of patients, Gu said.

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer — a median 17.5 months vs. 12.7 months — if they simultaneously received an immune stimulant, according to a study led by Dana - Farber Cancer Institute scientists.

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

They have identified a «checkpoint» manned by these immune cells that, if barred, can halt the development of the lung inflammation associated with allergies.

They suggest allocating greater resources to research focused on immune checkpoint therapies and targeted / immunotherapy combination therapies with «curative potential.»

One phase I trial of an immune checkpoint blockade drug combined with two established targeted therapies yielded 40 - 50 percent response rates among patients with metastatic kidney cancer.

Obesity is associated with increased inflammation, which could improve the effectiveness of checkpoint blockade drugs that unleash an immune response against cancer.

Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic mutations needed to enable the immune system to recognize and attack malignant cells.

«TCF - 1 is the focus of many immunology and oncology studies, especially those dealing with checkpoint inhibitors and sick immune cells.

Checkpoint blockade therapy works by interfering with cancer's ability to turn off the body's immune reaction.

«We are pleased to have obtained the same results in two different laboratories and we look forward to translating these preclinical findings into combination approaches with entinostat to enhance the clinical activity of immune checkpoint inhibition.»

AMD3100, alone or in combination with VIC - 008, decreases expression of the immune checkpoint molecule PD - 1 on CD8 T cells, implying that the CXCR4 / CXCR12 pathway modulates PD - 1 expression.

His team has recently reported that melanoma and lung cancer patients with more neoantigen - coding tumor mutations are more likely to respond to immune checkpoint blockers.

Due to an increasing body of evidence which suggests that the host immune response may be critical to the efficacy of oncolytic virotherapy, Shah and his colleagues also developed an immunocompetent melanoma mouse model and explored treating with both stem cell loaded oHSV and immune checkpoint blockers such as the ones that target the PD - 1 / PD - L1 pathway.

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

At that point, they began treatment with the drug pembrolizumab, which inhibits the PD - 1 immune checkpoint.

The combination could explain why relapse occurs in some patients with therapies targeting CTLA - 4 and PD - 1 checkpoints, which evade the body's immune system.

A CTLA -4-specific antibody, inhibiting the CTLA -4-mediated immune checkpoint, induces clinical regressions in patients with advanced melanoma (but also causes immune - related toxicity).

As demonstrated by the breadth of clinical trial involvement shown above, CCIR members are testing the utility of immune checkpoint blockade in lymphoma (shown by Dr. Allison to be effective against melanoma), genetic engineering in cell therapy (e.g., CD19, CXCR2, TGF - β DNR), and TLR agonists or IL - 2 in vaccine formulations as well as some novel combination therapies, such as the infusion of tumor - reactive lymphocytes from HLA - matched donors who were vaccinated with a lymphoma idiotype.

Through strategic partnerships with industry and nonprofit organizations, we gain access to a portfolio of priority drugs for testing within our expert focus groups, including checkpoint inhibitors, therapeutic vaccines, innate immune stimulants, targeted therapies, and many other promising treatments and technologies with high therapeutic potential.

The study compared four PD - L1 IHC diagnostic assays developed in conjunction with four PD - 1 / PD - L1 immune checkpoint inhibitors, which are used in NSCLC clinical trials.

Working in mice, Norbury's team used several methods to deplete different types of innate immune cells — collectively known as myeloid cells — at the three checkpoints before infecting the rodents with poxvirus.

One strategic avenue that Sharma and her colleagues are exploring to enhance checkpoint immunotherapy's effectiveness in more tumor types involves targeting other immune - related pathways in combination with existing immunotherapies.

Ongoing research involves the evaluation of immune checkpoint inhibition in collaboration with the Ludwig / CRI CVC trials network and the pharmaceutical industry.

Dr. Allison: The way the field of immunotherapy is going now is toward combinatorial therapies, where we combine these different immune checkpoints blockers, and also combine these with drugs that actually kill tumor cells.